"Systemic isotretinoin therapy normalizes exaggerated TLR-2-mediated innate immune responses in acne patients" Dispenza et al. Figure S1 : Mean (± SEM) lesion counts of acne patients on isotretinoin therapy: Inflammatory and non-inflammatory lesions were counted on the face (excluding the nose) of acne patients prior to (n = 25) and during isotretinoin therapy (1 week, n = 19; 4 weeks, n = 19; 8 weeks, n = 17; 20 weeks, n = 10) using standard visual counting techniques. The mean (± SEM) number of inflammatory lesions at baseline was 41 ± 6.3, and the mean (± SEM) number of noninflammatory lesions was 68 ± 17. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with patients' baseline counts.
: Serum levels of retinoids in acne patients and normal volunteers: Levels of the three retinoic acid isomers in the serum of normal volunteers (n = 19) and acne patients at baseline (n = 25), 1 week (n = 19), 4 weeks (n = 19), 8 weeks (n = 17), and 20 weeks (n = 10) of isotretinoin therapy were analyzed by HPLC/ mass spectrometry. Mean concentrations ± SEM are displayed. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with patients' baseline. Figure S3 : Isotretinoin does not affect peripheral Treg proportions: a) Lymphocytes from normal volunteers (Vols) (n = 11) and from patients at baseline (n = 14), 1 week (n = 13), 4 weeks (n = 11), 8 weeks (n = 10), and 20 weeks (n = 5) of isotretinoin therapy were treated for 5 days with P. acnes sonicate or anti-CD3/CD28 antibodies as above, whereupon they were stained with fluorescently-conjugated antibodies to T cell subset specific markers. Plots of CD25 versus Foxp3 expression among CD4+ cells are displayed for one representative patient. b) Mean percentages ± SEM of CD4+ T cells expressing CD25 and Foxp3 are shown for volunteers and acne patients during isotretinoin therapy.
